Clinical trial NCT01279291: Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Official title: Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasms
Ovarian Neoplasms
Fallopian Tube Neoplasms
Primary Peritoneal Neoplasm
Keywords: advanced solid tumor
Ovarian cancer
Primary peritoneal cancer
Fallopian tube cancer
Lead sponsor: Kyowa Kirin Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: Kyowa Hakko Kirin Pharma, Inc.
First posted: 2011-01-19
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a two-part, Phase 1, open-label, multicenter, dose escalation study of KHK2866 as monotherapy in patients with advanced solid tumors, and in combination with chemotherapy in subjects platinum-sensitive and platinum-resistant ovarian cancer.

Detailed description: During Phase 1a, groups of eligible patients with advanced solid tumors will receive KHK2866 as monotherapy in escalating doses. The Phase 1b portion will enroll patients with ovarian cancer who will receive KHK2866 in combination with one of three chemotherapy regimens (Arms): gemcitabine+carboplatin (platinum-sensitive, weekly paclitaxel (platinum-resistant), or pegylated liposomal doxorubicin (platinum-resistant). Escalating doses of the combination of KHK2866 and the chemotherapy regimen will given to two groups of subjects per Arm. The goal of the study is to learn about the side effects of KHK2866 alone or given in combination with chemotherapy. All subjects will receive study therapy for up to 6 cycles (up to 12 cycles for subjects assigned to PLD \[Arm 3 of Phase 1b\]), or until disease progression, the development of severe side effects, noncompliance or withdrawal of consent by the subject, or other removal criteria whichever comes first.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically documented, measurable or non-measurable, advanced primary or recurrent solid tumor (Phase 1a only) which is unresponsive to standard therapy or for which there is no standard therapy available.
* Histologically or cytologically documented ovarian, primary peritoneal, or fallopian tube cancer.
* The subject has objective radiographic disease progression and either unmeasurable or measurable disease during or following the last treatment regimen, or serum cancer antigen-125 (CA-125) greater than 2X the upper limit of normal (\[ULN\] \>70 U/mL
* Life expectancy \>3 months.
* Performance status \< 3 at study entry.
* Age \> 18 years.
* Normal left ventricular ejection fraction.
* Recovered from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer
* Preserved hepatic, renal, and hematopoetic organ function.
* Male and female subjects must use medically accepted contraception.

Exclusion Criteria:

* Ovarian malignancy of low malignant potential.
* Received anti-cancer chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or investigational agents within 4 weeks prior to the first dose of KHK2866 (6 weeks for nitrosourea or mitomycin chemotherapy).
* received Mabs or had major surgery within 4 weeks of the first dose of KHK2866.
* Requires administration of a prohibited medication or treatment including: prophylactic use of erythroid and/or granulocyte colony stimulating factors; concurrent anti-cancer treatment; biologic response modifiers for any condition
* Brain metastases, leptomeningeal or primary brain neoplasm, even if treated.
* Previously untreated or uncontrolled epidural metastasis
* Cerebrovascular accident, Transient ischemic attack; symptomatic head trauma, or seizures or any kind within 6 months
* Dementia, or other disorders of mentation or difficulty speaking or difficulty with comprehension.
* Suspected impending bowel obstruction
* The subject is pregnant,or is lactating.
* Significant uncontrolled intercurrent illness
* Known HIV infection or AIDS-related illness.
* Known active hepatitis B or C or other active liver disease.
* Psychiatric illness, disability or social situation that would compromise the subject's safety, ability to provide consent, or limit his/her compliance with study requirements.
* Experienced a unmanageable hypersensitivity reactions to Mabs or other therapeutic proteins.
* History of second primary cancer, with the exception of: a) curatively resected non-melanomatous skin cancer; b) curatively treated cervical carcinoma in-situ; or c) other primary solid tumor treated with curative intent and no known active disease present and no treatment administered during the last 2 years.
* Additional exclusion criteria for subjects proposed for enrollment into the Phase 1b portion:

  * History of hypersensitivity or infusion reaction to any of the proposed chemotherapy arm's agents that could not be controlled with pre-medication and/or infusion rate adjustment;
  * Prior treatment with KHK2866;
  * History of Grade ≥ 3 non-hematologic or Grade 4 hematologic toxicity attributable to any of the proposed chemotherapy arm's agents
  * For subjects proposed to receive treatment with KHK2866 plus PLD: prior total cumulative exposure to doxorubicin must be ≤ 240 mg/m2.
* Subjects with a known history of interstitial lung disease or pulmonary fibrosis. Subjects must have pulse oximetry \>88% on room air at rest, and a DLco of \>49% if there is no evidence of lung metastasis.

Primary outcomes:
measure: Number of Participants with Adverse Events as a Measure of Safety and Tolerability
timeFrame: at least 60 days, and up to 6 months
Secondary outcomes:
measure: To determine the Cmax, Tmax, AUC and half life of KHK2866 when administered i.v. as monotherapy
timeFrame: at least 28 days and up to 6 months
measure: To evaluate the changes in serum HB-EGf in participants administered KHK2866
timeFrame: at least 60 days, and up to 6 months
measure: To screen for the development of antibodies against KHK2866 (immunogenicity).
timeFrame: at least 60 days and up to 6 months
measure: To describe any anti-tumor activity observed when KHK2866 is administered i.v. as monotherapy, or in combination with chemotherapy.
timeFrame: at least 60 days and up to 6 months
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Arizona Cancer Center
state: Arizona
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center
state: California
city: Los Angeles
country: United States
facility: Cedar Sinai-Samuel Oschin Comprehensive Cancer Institute
state: California
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Houston
country: United States
facility: Oncology Consultants
state: Texas
city: San Antonio
country: United States
facility: Cancer Therapy and Research Center
state: Texas
Study officials:
affiliation: Kyowa Hakko Kirin Pharma, Inc.
name: Bruce A Silver, M.D.
role: STUDY_DIRECTOR
References:
citation: Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Target Oncol. 2016 Jun;11(3):317-27. doi: 10.1007/s11523-015-0394-5.